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The main limitation to the use of irinotecan in the treatment of colorectal cancer is the severity of side effects, including
neutropaenia and diarrhoea. Here, we explored the effects of 3 days of fasting on irinotecan-induced toxicities, on plasma, liver
and tumour pharmacokinetics and on anti-tumour activity in mice.
EXPERIMENTAL APPROACH
Male BALB/c mice received C26 colon carcinoma cells subcutaneously. They were randomized 1:1 into equally sized ad libitum fed
and fasted groups after which they were treated with irinotecan. Weight and adverse side effects were recorded daily. At the end
of the experiment, tumours were resected and weighed, and concentrations of irinotecan and its active metabolite SN-38 were
determined in plasma and tumour.
KEY RESULTS
Fasting prevented the diarrhoea and visible signs of discomfort induced by irinotecan. Ad libitum fed animals developed
leucopenia compared with untreated controls, whereas fastedmice did not. Irinotecan suppressed tumour growth equally in both
treated groups, compared with untreated controls. Levels of the active irinotecan metabolite SN-38 9 (calculated as AUC values)
were signiﬁcantly lower in fasted mice in both plasma and liver, but not in tumour tissue.
CONCLUSIONS AND IMPLICATIONS
Fasting protected against irinotecan-induced side effects without interfering with its anti-tumour efﬁcacy. Fasting induced a lower
systemic exposure to SN-38, which may explain the absence of adverse side effects, while tumour levels of SN-38 remained
unchanged. These data offer important new approaches to improve treatment with irinotecan in patients.Abbreviations
CES, carboxylesterase; DR, dietary restriction; IGF-1, insulin-like growth factor 1; PK, pharmacokinetic; SN-38, 7-ethyl-10-
hydroxycamptothecin (active metabolite of irinotecan); SN-38G, SN-38 glucuronide; UGT1A, uridine diphosphate glucu-
ronosyltransferase 1A© 2015 The British Pharmacological Society
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Effects of fasting on irinotecan treatment BJPIntroduction
Colorectal cancer is the second most prevalent cancer, with
more than 1.2 million new cancer cases and over 600 000
deaths per year (Jemal et al., 2011). About 15–20% of patients
at initial presentation have liver metastases, and an addi-
tional 45% are diagnosed with metastases in follow-up after
resection of the primary tumour (Adam, 2007). A potent
anti-cancer agent in ﬁrst-line and second-line treatment for
unresectable and metastatic disease is irinotecan (CPT-11), at
present the most widely used topoisomerase-I inhibitor.
Irinotecan can produce severe and unpredictable haemato-
logical, intestinal and systemic toxicities, including profound
myelosuppression, massive diarrhoea, vomiting, fatigue and
in some cases even death as a complication of the other side
effects (Rowinsky et al. 1994; Rothenberg 1998; Kim and
Innocenti 2007; Ramchandani et al. 2007). It is generally ac-
cepted that this toxicity is mediated by the active metabolite
of irinotecan, 7-ethyl-10-hydroxycamptothecin (also known
as SN-38) (Mathijssen et al. 2001). Importantly, irinotecan is
one of the chemotherapeutic drugs that has been reported
to generate high levels of oxidative stress (Conklin 2004),
leading to failure of normal cellular functions and may con-
tribute to the toxicities already discussed (Chen et al. 2007).
Fasting is a powerful means to increase resistance against
acute stressors such as oxidative stress. We have previously
shown that preoperative fasting and dietary restriction (DR)
protected against acute oxidative damage induced by
ischaemia–reperfusion injury in both kidney and liver (van
Ginhoven et al. 2009; Mitchell et al. 2010; Van Ginhoven et al.
2010b; Verweij et al. 2011). In addition, preoperative DR reduced
hepatic tumour load and the hepatic expression of the endothe-
lial cell speciﬁc adhesion molecule, E-selectin (van Ginhoven
et al. 2010a). It has been suggested that fasting protects normal
cells by rearrangement of energy into maintenance pathways
instead of reproduction and growth (Raffaghello et al. 2008;
Lee et al. 2012). In this way, DR could protect against toxic side
effects of anti-cancer drugs, but how this affects pharmacokinet-
ics and anti-tumour activity is still largely unknown.
Therefore, in this study, we have examined the effects of
fasting prior to administration of a high dose of the
chemotherapeutic agent irinotecan on the occurrence of side
effects and anti-tumour activity in mice bearing the C26
colon carcinoma-. In addition, to elucidate the mechanism
involved, we have examined the pharmacokinetics of
irinotecan in plasma, liver and tumour of mice, following
3 days of fasting.Methods
Animals
All animal care and experimental protocols complied with
the 1986 directive 86/609/EC of the Council of Europe and
were approved by the Animal Experiments Committee, under
the Dutch National Experiments on Animals Act. Studies in-
volving animals are reported in accordance with the ARRIVE
guidelines for reporting experiments involving animals
(Kilkenny et al. 2010; McGrath et al. 2010).
Male inbred strains of mice (BALB/c) of 6–8 weeks old –
weighing approximately 25 g –were obtained fromCharles River,
Maastricht, The Netherlands. Upon arrival, animals were housed
at random in individually ventilated cages (n = 3–4 animals per
cage) in a licensed biomedical facility at Erasmus University
Medical Center, Rotterdam, TheNetherlands. Standard laboratory
conditions weremaintained, with temperature ~ 22 °C, humidity
~50% and a 12 h light/12 h dark cycle. All mice had free access to
watr and food (Special Diet Services, Witham, UK) unless
mentioned otherwise. Animals were allowed to acclimatize
for 1 week before the start of the experiments.Fasting protocol
Mice in the ad libitum fed groups were allowed unrestricted
access to food. Before the start of the experiment, all mice
were transferred to a clean cage and, in the fasting groups,
food was withheld for 3 days starting at 16:00 h. All animals
were given continuous access to water.C26 colon carcinoma cells
The murine colon carcinoma cell line C26 was kindly
provided by Dr. R. Schiffelers (Utrecht Medical Centre, The
Netherlands). The C26 cell line originally derived from the
BALB/c mouse and was cultured in DMEM (Sigma Aldrich,
St. Louis, MO, USA), supplemented with 10% foetal calf se-
rum (Lonza, Verviers, Belgium), penicillin (100 units mL1)
and streptomycin (100 units mL1) (Invitrogen, Auckland,
New Zealand) at 37 °C in a 5% carbon dioxide environment
(Sato et al. 1981). Cells were collected by brief trypsinization
(0.05% trypsin in 0.02% EDTA). For s.c. injection, cells were
collected and, after centrifugation, single-cell suspensions
were prepared in PBS to a ﬁnal concentration of 5.0 × 105
cells per 100 μL. Cell viability was determined by Trypan
blue staining and was always ≥90%.British Journal of Pharmacology (2016) 173 804–814 805
Figure 1
Protective effects of fasting against irinotecan toxicity. A total of 24 mice, six mice per group, were observed for adverse side effects for 10 days after
the ﬁrst irinotecan injection; irinotecan was given i.p. on days 1, 3 and 5 after fasting (shown by *). (A) Effect of fasting on body weight. Fasted (F) mice
lost about 20% of their body weight during 3 days’ fasting. During irinotecan treatment, ad libitum (AL) fed mice showed 20% weight loss, while
fastedmice gainedweight and reached their startingweight at day 5. (B–E) Effects of fasting on activity (B); coat (C); diarrhoea (D) and the posture
of the mice (E). Data shown are means ± SEM (n = 6). **P = 0.003, *** P < 0.001, signiﬁcantly different from (F + irino) group; one-way ANOVA
with Bonferroni’s correction. (F) Effect of fasting on circulating leukocyte numbers, measured on day 8 after the ﬁrst irinotecan injection.
Fasting alone did not affect leukocyte levels. The mice fed ad libitum and treated with irinotecan (AL+ irino) showed leukopenia compared with
fasted mice treated with irinotecan (F + irino). *** P < 0.001, signiﬁcantly different as indicated; one-way ANOVAwith Bonferroni’s correction.
BJP S A Huisman et al.Chemotherapy
Irinotecan, HCl trihydrate 20 mg mL1 (Hospira Benelux,
Antwerp, Belgium) was used for in vivo experiments. The
irinotecan was diluted in sodium chloride 0.9% (Braun,
Melsungen, Germany) to a ﬁnal volume of 200 μL per injec-
tion and was given i.p. Optimal drug doses were determined
in a pilot experiment (Supporting Information Fig. S1).Effect of fasting on irinotecan-induced side
effects
A total of 24 mice were anaesthetized with isoﬂurane inhala-
tion (2%). Body temperature was maintained by placing the806 British Journal of Pharmacology (2016) 173 804–814mice on heating pads. A lateral incision on the right ﬂank
was made to implant a tumour cube, derived from mice
carrying C26 tumours subcutaneously. All mice received
0.05 mg kg1 buprenorphine (Temgesic, Schering Plough,
Houten, The Netherlands) via s.c. injection before the
implantation of tumours. Tumour cubes measured approxi-
mately 15 mm3 and were implanted at least 4 mm away from
the incision site. Mice were randomly divided into four
groups (n = 6 per group): group 1, ad libitum fed group
receiving vehicle treatment; group 2, fasting group receiving
vehicle treatment; group 3, ad libitum fed group receiving
irinotecan; and group 4, fasting group receiving irinotecan
treatment. The irinotecan treatment was given i.p., after
Effects of fasting on irinotecan treatment BJP3 days of fasting or ad libitum food, on days 1, 3 and 5, as three
equal injections amounting to a cumulative, weight-adjusted
dose of 400mg kg1 (see Fig. 1A). The control groups received
vehicle treatment (sodium chloride 0.9%). From the ﬁrst
irinotecan injection, mice were weighed and inspected daily
for adverse side effects using a mouse well-being score
protocol adapted from the Guidelines for welfare of animals
in experimental neoplasia research (UK Co.-ordinating
Committee on Cancer Research, 1988). Assessing well-being
by one researcher took approximately 10 min per cage with
four mice. Side effects were scored independently by two ex-
perienced researchers. Mouse cages were removed from racks
and placed on a bench to facilitate visualization of the mice,
but cages were not opened at any point during the scoring
process, except for the determination of the stool consistency
at the end of the visual examination. Mouse activity level was
scored according to the amount each mouse moved in its
cage. A score of 2 indicates that an animal moved around
the cage normally. A score of 1 indicates that an animal was
moving slowly or less frequently and with an altered gait. A
score of 0 indicated that an animal was not moving and was
taking no more than ﬁve steps. The appearance of the coat
was scored according to the smoothness. A score of 2
indicated a healthy, smooth uninterrupted coat. A score of 1
indicated a slightly ﬂuffy coat. A score of 0 indicated a se-
verely ﬂuffy coat with obvious gaps with visible skin. Severity
of diarrhoea was assessed according to the stool consistency
score (0: normal, 1: loose stool, 2: loose/some diarrhoea, 3:
diarrhoea and 4: severe watery diarrhoea) (Fitzpatrick et al.
2011). Before every stool consistency measurement, clean
white tissues were placed at the bottom of the cage to allow de-
termination of the consistency of the stool. Posture was scored
as follows. A score of 2 indicated a normal body posture. A score
of 1 indicated a moderately hunched posture. A score of 0 indi-
cated a severely hunched posture. Results are expressed as
mean ± SEM. Leukocyte numbers were determined on day 8
after the ﬁrst irinotecan injection with a Z series Coulter
Counter (Beckman Coulter, Woerden, The Netherlands). Ten
days after the ﬁrst irinotecan injection, mice were killed by
exsanguination. Tumours were resected and weighed.Effects of fasting on irinotecan
pharmacokinetics
A total of 54 mice were anaesthetized with isoﬂurane inhala-
tion (2%). The right lateral ﬂank was shaved for precise injec-
tion. A suspension of C26 cells (5.0 × 105 cells in a volume of
100 μL) were injected, using a 21 G needle. Growth kinetics
following C26 tumour cube implantation were similar to
growth after injection of C26 cells (Supporting Information
Fig. S2). Tumours were allowed to grow for 14 days before
the start of the experiment. The mice were randomly divided
into three groups (n = 18 per group). Two groups were fasted
for 3 days, and one group was fed ad libitum. After the fasting
period, mice were fed ad libitum again. The ad libitum fed
group and one group of fasted animals were treated with a
single weight-adjusted dose of 100 mg kg1 (±2.5 and
±2.0 mg, respectively) of irinotecan i.p. The other fasted
group received a ﬂat-ﬁxed dose. This dose contained the same
concentration as in ad libitum fed mice (2.5 mg), which were
approximately 20% heavier compared with the fasted mice.The ﬂat-ﬁxed-dose group was included to provide an alterna-
tive dosing to correct for bodyweight loss in fasted animals,
especially during the ﬁrst irinotecan injection. At 1, 4, 8, 12,
24 and 48 h after irinotecan injection, mice were killed by
exsanguination, and 100 μL plasma, 100 μg liver and 100 μg
tumour were collected. Each time point included three mice
per group.
Tissue pretreatment
Tumour and liver samples were obtained and kept frozen at
70 °C until used. Tissues were diluted in human plasma
(1:4w/v) into a 2 mL Eppendorf tube. Hereafter, a 5 mm stain-
less steel bead (Qiagen, Venlo, The Netherlands) was added,
and the samples were homogenized with a Tissuelyser
(Qiagen, Venlo, The Netherlands) and processed for 4 min at
40 Hz. Beads were removed, and homogenized samples were
stored at 70 °C until analyses. Homogenized tissue samples
were further processed as plasma samples.
Determination of irinotecan, SN-38 and SN-38
glucuronide concentrations
Total irinotecan and total SN-38 were quantiﬁed using a
validated method involving reversed-phase HPLC with ﬂuo-
rescence detection as described earlier (de Bruijn et al. 1997;
Sparreboom et al. 1998; de Bruijn et al. 2004). All frozen sam-
ples were thawed at 4 °C and were homogenized by vortex
mixing. A 250 aliquot of plasma was mixed for 10 min with
500 μL 5%perchloric acid–methanol (1:1, v/v) in 1.5mL poly-
propylene tubes (Eppendorf, Hamburg, Germany). After cen-
trifugation for 5 min at 18 000 × g, 250 μL of the clear
supernatant was mixed with 250 μL phosphate buffer. Hereaf-
ter, 100 μL was injected into the HPLC system. Chromato-
graphic analysis was performed using an Agilent® HPLC
system 1100 series (Agilent Technologies, Santa Clara, CA).
Chemstation software was used for datamonitoring and anal-
ysis. Separation of the compounds was achieved using an
Inertsil ODS 80A (4.6 mm × 150 mm, 5 μm particle size)
analytical column. The analytical column was maintained
at a temperature of 50 °C. A gradient at a ﬂow rate of
1.00 mL min1 was achieved with mobile phase A, composed
of 0.1 M ammonium acetate containing 0.01 M tetra-butyl-
ammonium sulphate and mobile phase B composed of meth-
anol. A linear gradient was used, with 67–50% mobile phase
A, from 0 to 25 min, followed by 50–10% mobile phase A
for 5 min. This was succeed by a linear gradient back to 67%
mobile phase A from 30 to 31 min, which was held for
2 min to re-equilibrate. The column eluent was monitored
ﬂuorometrically at an excitation wavelength of 375 nm and
an emission wavelength of 460 nm for detection of
irinotecan and an excitation wavelength of 380 nm and an
emission wavelength of 532 nm for the detection of SN-38.
Calibration curves were computed using the ratio of the peak
height of irinotecan or SN-38 versus the nominal con-
centration, with a lower limit of detection of 5.00 ng mL1
for irinotecan and 0.500 ng mL1 for SN-38. Uridine diphos-
phate glucuronosyltransferase 1A (UGT1A) inactivates
SN-38 by conversion to its glucuronide form, SN-38 glucuro-
nide (SN-38G). SN-38G in plasma samples was quantiﬁed by
the amount of SN-38 released following treatment for 3 h
at 37 °C with 100 U of Escherichia coli β-glucuronidase.British Journal of Pharmacology (2016) 173 804–814 807
BJP S A Huisman et al.Concentrations from 48 h samples were below the detection
limit, and therefore, we report data only from0 to 24h sampling
points.Figure 2
Effect of irinotecan treatment on tumour growth in fasted and ad
libitum fed groups. At the end of the experiment, irinotecan-treated
tumours were signiﬁcantly smaller in both the fasted (F) and ad libitum
(AL) fed groups compared with untreated controls. Data shown are
means ± SEM (n = 6). ***P < 0.001, signiﬁcantly different as indi-
cated; one-way ANOVAwith Bonferroni’s correction. Fasting alone
had no signiﬁcant effect on tumour weight.Real-time quantitative reverse-transcription
PCR
RNAwas isolated from liver and tumour tissues collected at 1,
8 and 12 h after irinotecan injection from the ad libitum fed
and fasted groups (ﬂat-ﬁxed dose) using a TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) according to the manufac-
turer’s instructions. To avoid genomic DNA contamination,
RNA was puriﬁed by a DNAse treatment (RQ1 RNase-Free
DNase; Promega, Madison, WI, USA). RNAwas then reverse
transcribed into cDNA using random primers (Invitrogen)
and Superscript II RT (Invitrogen). Gene expression
was analysed by real-time quantitative PCR using an
Applied Biosystems 7700 PCR machine (Foster City, CA,
USA). Reverse-transcription PCR was performed for
carboxylesterase 2 (CES2) forward, 5-ggccatgtgtctgcaaaatc-3,
and reverse, 5-caccatcacaggcaggttag-3. GAPDH was used as a
housekeeping gene. Each sample was tested in triplicate.
ΔCt values were normalized to the average ΔCt of the ad
libitum fed group. The fold change was calculated using the
Pfafﬂ equation, 2  ΔΔCt.Data analysis
For each set of variables, means ± SEM were computed. All
standard statistical tests were performed using SPSS version
21 for Windows software (Statistical Package for Social
Sciences, Chicago, IL, USA), and P < 0.05 was considered to
show signiﬁcant differences between means. One-way ANOVA
was used to assess whether fasting signiﬁcantly altered side
effects with the Bonferroni correction applied to correct for
multiple testing. To analyse the pharmacokinetic (PK) data,Figure 3
Pharmacokinetics of irinotecan (circles) and SN-38 glucuronide (triangle
Time curves are presented for ad libitum fed groups (black symbols), fasted w
squares). Fasted weight-adjusted dosed and fasted ﬂat-ﬁxed dosed animal
irinotecan AUC values in the liver and tumor are lower in fasted animals. SN
and SN-38G AUC values are lower in plasma. SN-38 AUC values in tumor ti
808 British Journal of Pharmacology (2016) 173 804–814Phoenix WinNonlin version 6.1 (Certara USA Inc., St. Louis,
MO, USA) software was used. A plasma concentration-time
curve for 0-24 h was generated by joining up the highest
values at each time and the AUC for that curve calculated.
Similarly, the lowest values for each time provided the
lowest curve with its corresponding AUC. The remaining
(intermediate) values then generated an intermediate curve
with its derived AUC. Student’s t-test was used to determine
statistical differences.s) and SN-38 (squares) in plasma, tumor and liver. Concentration-
eight-adjusted dosed (white circles) and fasted ﬂat-ﬁxed dosed (grey
s show a trend towards higher plasma irinotecan AUC values, while
-38 AUC values are lower in both fasted groups in plasma and liver,
ssue show large variation.
Figure 4
Statistical validation of pharmacokinetic differences. Data shown are the AUC values for each experimental group. No signiﬁcant differences were found
for irinotecan AUC values between ad libitum (AL) fed, weight-adjusted dosed fasted (F) and ﬂat-ﬁxed dosed fasted (F ﬂat) groups in plasma (A + B),
liver (D + E) and tumour (F + G). SN-38 AUCvalues in plasma (B) were signiﬁcantly lower inweight-adjusted dosed fasted animals (*P = 0.02), and
SN-38G AUC values in plasma (C) were signiﬁcantly lower in weight-adjusted dosed fasted animals and fasted ﬂat-ﬁxed dosed animals *P = 0.04,
**P = 0.01. SN-38 AUCvalues in the liver (E) were signiﬁcantly lower in both fasted groups **P = 0.003. No signiﬁcant differences were seen in SN-
38 AUC values for tumour tissues; P = 0.27. n = 3; differences as indicated; Student’s t test.
Effects of fasting on irinotecan treatment BJPResults
To study the effect of fasting on irinotecan toxicity, we ﬁrst
treated ad libitum fed mice with different doses of irinotecan.
Using cumulative doses of 500, 600 and 800 mg kg1, given
in three doses over 5 days all mice died within 11 days from
the ﬁrst injection (Supporting Information Fig. S1). Using a
cumulative dose of 400 mg kg1, also given over 5 days, mice
experienced serious adverse effects like diarrhoea, hair loss
and a rufﬂed coat but survived and recovered within the
15 day observation period. Therefore, we decided to use the
cumulative dose of 400 mg kg1 in our ﬁrst experiments.Fasting protects against the adverse side effects
of irinotecan and does not affect anti-tumour
activity
To examine the effects of fasting before irinotecan adminis-
tration on the occurrence of irinotecan-induced side effectsand anti-tumour effect in C26 colon carcinoma-bearingmice,
we compared 3 day fasted with ad libitum fed mice. In the ad
libitum fed group, mice showed weight loss from the ﬁrst
irinotecan injection, while the fastedmice gained weight dur-
ing the treatment and observation period (Figure 1A).
From day 4 after the ﬁrst irinotecan injection, other side
effects were observed in the ad libitum fed group. They were less
active (P = 0.003), had a rufﬂed coat (P < 0.001), suffered more
from diarrhoea (P < 0.001) and showed a hunchback posture
(P< 0.001) (Figure 1B-E). The fasted mice showed none of these
visible side effects. On day 8 after the ﬁrst irinotecan injection,
the fasted group had a signiﬁcantly higher blood leukocyte
count than that from the ad libitum group (P< 0.001) (Figure 1f).
No animals died during the experimental period (15 days) in
irinotecan treated groups. At the end of the experiment, all tu-
mours were resected and weighed. Irinotecan-treated tumours
were signiﬁcantly smaller in both fasted and ad libitum fed
groups, compared with untreated controls (P < 0.001). Fasting
alone had no signiﬁcant effect on tumour growth (Figure 2).British Journal of Pharmacology (2016) 173 804–814 809
Figure 5
CES2 mRNA expression in liver and tumour tissue from ad libitum fed and fasted mice. CES2 expression at 1 (t = 1), 8 (t = 8) and 12 h (t = 12)
after irinotecan injection in liver and tumour tissue from ad libitum (AL) fed and fasted (F) animals did not reveal any signiﬁcant
differences.
BJP S A Huisman et al.Taken together, these results show that 3 days of fasting prior
to treatment with a high dose of irinotecan prevented many of
the side effects but did not modify its anti-tumour effects.Fasting reduces the systemic exposure to SN-38
To elucidate the mechanism of fasting-induced resistance
against its side effects, we examined the pharmacokinetics
of total irinotecan and its active metabolite SN-38 in plasma,
liver and tumour tissue of 3 day fasted and ad libitum fed
mice. Furthermore, SN-38G concentrations were measured
in plasma to indicate the activity of UGT1A, the major
metabolizing enzyme for SN-38 (Figure 3).
To express differences between AUCs more clearly and to
perform statistics on these curves, ﬁgures were computed
where the highest, intermediate and lowest AUC values were
plotted (Figure 4A-G). Note that because the levels of SN-38
and SN-38G at 48 h were too low for reliable measurements,
the AUC for these substrates is reported as AUC0-24. The
AUC values of the active metabolite SN-38 were signiﬁcantly
lower in plasma and liver in fasted animals compared with
that from ad libitum fed animals, while in the tumour, SN-38
AUC values did not differ between fasted and ad libitum fed
animals.
Plasma AUC values of irinotecan were not signiﬁcantly
different between the three groups, although there was a
trend towards higher AUC values in the fasted groups
(Figure 4A). For SN-38, the AUC values were reduced, by
51%, in the weight-adjusted dosed fasting group (mean
AUC0-24 0.56 vs. 1.15 mg*h mL
1) but not signiﬁcantly in
the ﬂat-dosed fasting group, compared with ad libitum fed
controls (Figure 4B). However, the AUC for SN-38G was
reduced, by 51% and 35%, in the weight-adjusted dosed
fasting group and the ﬂat-dosed fasting group, respectively,
compared with ad libitum fed controls (mean AUC0–24 8.3
vs. 16.9 μg * h mL1, P = 0.01, and AUC0–24 11.0 vs. 16.9 μg
* h mL1, P = 0.04, Figure 4C).
In the liver, there were no differences between the AUC
values for irinotecan, from the three experimental groups
(Figure 4D) but for the active metabolite SN-38, both the
weight-adjusted dosed fasting group (mean AUC0–24 15.5 vs.
29.2 ng * h mg1, P = 0.003; 47% reduction) and the ﬂat-
dosed fasting group (mean AUC0–24 17.1 vs. 29.2 ng * h mg
1,810 British Journal of Pharmacology (2016) 173 804–814P = 0.003, 41% reduction), showed lower AUC values than
those from the ad libitum fed group (Figure 4E).
In the tumour tissue samples, no differences were found
between AUCs for irinotecan in the ad libitum fed controls
and the two fasted groups (Figure 4F). Interestingly, SN-38
AUC values in tumour tissue, in contrast to those in plasma
and liver, showed no signiﬁcant changes in the fasted groups,
compared with the ad libitum fed controls (Figure 4G), only a
trend towards increased values. Although these increases
were not signiﬁcant, our results imply that the intratumour
SN-38 concentrations did not decrease after fasting.
These data demonstrated that, although irinotecan AUC
values were not changed in fasted animals, the AUC values
for SN-38 and its glucuronide were signiﬁcantly lower in
plasma and liver tissue from fasted animals, indicating that
3 days of fasting prior to irinotecan administration induced
an important change in its metabolism and lowered the
systemic exposure to the cytotoxic metabolite SN-38.Carboxylesterase-2 (CES2) in liver and tumour
Conversion of irinotecan to SN-38 occurs mainly in the liver
and is catalysed by the CES enzymes. Fasting is known to af-
fect liver function and size and, therefore, hepatic CES and
its metabolism of irinotecan may be changed during fasting.
We measured levels of CES2 by its mRNA expression at 1, 8
and 12 h, after irinotecan injection in liver and tumour tissue
from ad libitum fed and fasted animals. There were no signif-
icant differences in CES2 expression levels between ad libitum
fed and fasted groups in liver and tumour tissue (Figure 5).Discussion
The experiments presented in the current study showed that
3 days of fasting prior to treatment with a high dose of
irinotecan prevented the occurrence of drug-related side ef-
fects while anti-tumour efﬁcacy was not affected. To elucidate
the mechanisms behind the fasting-induced protection from
irinotecan-induced side effects, we studied the pharmacoki-
netics of this drug in fasted and fed mice. We found no differ-
ences in irinotecan AUC values between fasted and ad libitum
fed animals and demonstrated that the AUC of the active and
Effects of fasting on irinotecan treatment BJPtoxic metabolite of irinotecan, SN-38, was lower in plasma
and in liver tissue from fasted animals. Furthermore, AUC
values for the SN-38 metabolite, SN-38G, were signiﬁcantly
lower in plasma from fasted animals. The AUC values for
SN-38 in tumour samples in fasted mice remained un-
changed. These data indicated that fasting induced impor-
tant changes in irinotecan metabolism and lowered the
systemic exposure to irinotecan and SN-38.
A remarkable ﬁnding in this study was that the 3 day
fasted BALB/c mice did not show any signs of toxicity in re-
sponse to a high dose of irinotecan. In contrast, animals
regained the weight that was lost during the fasting period, ap-
proximately 20%, during the three days of high-dose irinotecan
treatment, while control animals lost approximately 20% of
their bodyweight during both irinotecan exposure and the sub-
sequent observation period. It is currently thought that fasting
induces a hormetic response. This is a common biological phe-
nomenon in which exposure to a low-intensity stressor induces
a general adaptive response that has beneﬁcial effects, including
protection against different types of stress (Mattson 2008a,
2008b). We observed relevant differences in irinotecan pharma-
cokinetics between ad libitum fed and fasted mice. In plasma
from fasted mice, there was a trend towards higher AUC values
of irinotecan compared with ad libitum fed mice, while SN-38
AUC values in plasma from fasted mice were clearly lower com-
paredwith those in ad libitum fed groups. In the liver, therewas a
trend towards lower AUC values of irinotecan in fasted mice,
and AUC values of SN-38 were signiﬁcantly lower in fasted
groups compared with those in ad libitum groups. SN-38 is ap-
proximately 100–1000-fold more cytotoxic than its pro-drug,
irinotecan (Mathijssen et al. 2001). Irinotecan is converted to
SN-38 primarily in the liver. Catalysed by CES enzymes, but in
patients, this conversion is rather inefﬁcient (only 2–5%) when
irinotecan is injected intravenously (Cao et al. 2006; de Jong
et al. 2006). Therefore, it is thought that intratumour CES ex-
pression is responsible for the anti-tumour effect in patients
(Xu et al. 2002). We found reduced levels of SN-38 in liver and
plasma of fasted mice, but CES expression in liver and tumour
tissue was not altered in thesemice. Tumour cells have the same
if not higher levels of SN-38, but CES expression was not higher
in tumour cells of fasted mice. This may indicate that tumour
cells of fasted mice are taking up more SN-38 rather than that
metabolism by CES is higher in fasted mice. The glucuronide
synthase UGT1A is capable of inactivating SN-38 by conversion
to its glucuronide form SN-38G, leading to its excretion from
the circulation (Di Paolo et al. 2006). We showed signiﬁcantly
lower SN-38G AUC values in plasma from fasted mice, indicat-
ing that the lower amount of SN-38 in plasma was not due to
increased UGT1A activity.
In an attempt to explain the differential effects of fasting
on the systemic level versus tumour tissue, the term ‘differen-
tial stress resistance’ has been coined (Raffaghello et al. 2008;
Longo and Mattson 2014). Drug metabolism can be largely
divided into three phases: phase I (redox and hydrolysis),
phase II (conjugation) and phase III (transport). Diet and nu-
trient signalling pathways have important effects on phase I
enzymes (Mathijssen et al. 2014). These enzymes consist pri-
marily of cytochrome P450 superfamily proteins (Yang et al.
1992) and phase II proteins including enzymes regulated by
Keap1-Nrf2 (Kohle and Bock 2007). During fasting, signiﬁ-
cant modulation of these pathways occurs in healthy tissue,but not in tumour tissue. We have previously shown that
3 days of fasting up-regulates canonical stress resistance path-
ways such as Nrf2, ‘xenobiotic metabolism’ and effector
genes such as haem-oxygenase I, superoxide dismutase and
glutathione-S-transferase (Mitchell et al. 2010; Jongbloed
et al. 2014). These data may partly explain the concept of
differential stress resistance, which predicts that these
pathways are differentially regulated by fasting, in healthy
compared with tumour tissue. How this affects pharmacoki-
netics and anti-tumour efﬁcacy has remained unknown. We
hypothesized that during fasting, cells in the liver (among
others) up-regulate stress resistance pathways, which de-
creases conversion of irinotecan, whereas in the tumour,
these pathways are unaffected. This supposition is strength-
ened by the fact that SN-38 AUC values remained unchanged
in tumours of fasted mice.
Fasting is known to down-regulate insulin-like growth
factor-1 (IGF-1) levels (Mitchell et al. 2010), which has a
plethora of downstream effects that are likely to be linked to
the protective effect induced by fasting. Many intrinsic fac-
tors may inﬂuence the PK of irinotecan (Mathijssen et al.
2001) and IGF-1 has been related to the outcome of combined
treatment with cetuximab + irinotecan in humans (Scartozzi
et al. 2010). However, to the best of our knowledge, IGF-1
has never been related to the PK of irinotecan in vivo and
potential interactions between IGF-1 and irinotecan PK
cannot be determined from the results presented here.
In earlier studies, protective effects against toxic agents
have also been observed when animals were subjected to
long-term restriction of food intake (DR), rather than fasting,
which is the total absence of food.Mice subjected to 5–8months
40% DR were signiﬁcantly more resistant against paraquat tox-
icity than ad libitum fed mice (Sun et al. 2001). Rats allowed to
eat only 65% of their normal intake for 3 weeks showed in-
creased resistance to thioacetamide due to increased liver tissue
repair mechanisms (Apte et al. 2003). Moreover, rats that were
40% calorically restricted for 4 weeks showed increased resis-
tance against bleomycin-induced DNA damage (Aidoo et al.
1999). We have shown that the beneﬁcial effect of DR on acute
stress resistance can be induced rapidly, as 3 days of fasting
protected against oxidative damage induced by renal ischaemic
injury, similar in magnitude to 2–4 weeks of 30% DR (Mitchell
et al. 2010). On a systemic level, we found an overlapping tran-
scriptional response, indicating that short-term fasting and
long-term DR induce potentially overlapping mechanisms. Fur-
thermore, an ad libitum diet deﬁcient in protein or amino acids
protectedmice in a surgical ischaemia–reperfusion injurymodel
(Peng et al. 2012). More recently, a study in dogs with
lymphoma that were treated with doxorubicin showed that
24 h of fasting immediately before administration resulted in
signiﬁcantly lower incidence of vomiting (Withers et al. 2014).
Implementation of DR and fasting in the clinic is still labori-
ous. We have shown that preoperative DR and fasting are feasi-
ble and safe in surgical patients (van Ginhoven et al. 2009,
2011). Furthermore, women at risk for breast cancer showed re-
duced inﬂammation and oxidative stress during a diet of 2 days
fasting per week (Harvie et al. 2011). Asthma patients main-
tained for 8 weeks on an alternate day fasting diet exhibited less
clinical symptoms, pulmonary functions were improved and
oxidative stress and inﬂammation declined during the diet
(Johnson et al. 2007). Based on the existing evidence fromBritish Journal of Pharmacology (2016) 173 804–814 811
BJP S A Huisman et al.animal and human studies, there is great potential in translating
these results to clinical cancer patients. In a self-reported study
of patients with a variety of malignancies, a voluntarily fasting
regimen prior to (48–140 h) and/or following (5–56 h) chemo-
therapy resulted in a decrease of common side effects and
increased subjective well-being (Safdie et al. 2009). These data
suggest that fasting is safe and feasible and might offer impor-
tant new opportunities to improve chemotherapy treatment
in cancer patients. However, development and completion of
randomized controlled clinical trials are essential in fulﬁlling
its clinical potential.
It is known that ectopic and orthotopic tumour environ-
ments can respond differently to a variety of treatments.
However, in a recent study using FabplCre;Apc15lox/+ mice,
which spontaneously develop intestinal tumours, fasting re-
duced tumour growth, as it did in ad libitum fed mice and
protected against the side effects of irinotecan (Huisman
et al. 2015). However, the results from this orthotopic tumour
model do not directly prove that differential alteration of PK
is the primary mechanism underlying protection from side
effects and this possibility will need further investigation.
We have shown here that fasting protected against the side
effects of one cycle of irinotecan treatment. It remains un-
clear if cancer cells are sensitized or not by multiple cycles
of fasting/irinotecan treatment in this experimental model.
However, a recent study suggested that multiple cycles of
fasting induced differential stress sensitization in a range of
tumours (Lee et al. 2012).
In summary, the present study showed that short-term
fasting protected against the adverse side effects of irinotecan
in C26 colorectal carcinoma-bearing mice without interfer-
ing with anti-tumour activity. This reduction of side effects
may have been the result of the lower systemic exposure to
SN-38 in fasted, compared with ad libitum fed mice. When
conﬁrmed in clinical trials, fasting before irinotecan treat-
ment may offer important new opportunities to improve this
treatment for patients with colorectal carcinoma.Acknowledgements
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Figure S1 Survival of ad libitum fed mice treated with differ-
ent doses of irinotecan. Ad libitum fed mice (n = 6 per group)British Journal of Pharmacology (2016) 173 804–814 813
BJP S A Huisman et al.were treated on days 1, 3 and 5 after fasting with a cumulative
dose of 400, 500, 600 or 800mg kg1 irinotecan (shown by *).
Using 500, 600 and 800 mg kg1 irinotecan, all animals had
to be killed within 14 days, because of the severity of side
effects induced by the irinotecan treatment. With a dose of
400 mg kg1, all mice survived and recovered from the side
effects of irinotecan.
Figure S2 Tumour surface of ad libitum fed mice im-
planted with tumour cubes or injected with tumour cells.814 British Journal of Pharmacology (2016) 173 804–814Ad libitum fed mice (n = 6 per group) were implanted with
C26 tumour cubes (approximately 15 mm3) or injected
with 5.0 × 105 C26 tumour cells, on day 0. On day 5 after
injection, tumours were macroscopically visible in the
group injected with cells and showed growth kinetics,
similar to those of the tumour cubes, over the subsequent
period of implantation. On the day of harvesting the tu-
mours (days 21 or 25), both groups had a similar tumour
surface (P > 0.05).
